A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

NCT01149421 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication LY2189265 on blood pressure and heart rate in adults with type 2 diabetes over a 16-week period.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 755 people

Who can join Ages 18+ · all sexes

Timeline Started 2010-06 · est. completion 2012-01

Where 76 sites · Argentina, Brazil, Canada, Czechia, Denmark, India, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT01149421 ↗

Description as written by the study sponsor.

The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).

Treatments tested

LY2189265 also known as Dulaglutide Drug

Administered as a subcutaneous injection once weekly for 26 weeks
Placebo Drug

Administered as a subcutaneous injection once weekly for 26 weeks

Main thing measured	Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01149421 ↗